Clinical Overview

Folliculitis decalvans (FD) represents a suppurative scarring alopecia characterized by recurring pustular folliculitis and bacterial infection leading to scarring and permanent hair loss. The condition typically presents with clusters of pustules on the scalp, often with follicular exudation, crusting, and characteristic "keypunch" appearance of follicle destruction. FD creates islands of scarring alopecia surrounded by normal-appearing scalp, with progressive coalescence into larger alopecic areas if untreated. The primary pathophysiology involves bacterial infection superimposed on follicular inflammation, though the precise mechanism triggering recurrent folliculitis remains incompletely understood.

Epidemiology and Microbiology

Folliculitis decalvans shows peak incidence in 20-40 year-old males, though affects females and other age groups. African-descent individuals show potentially higher prevalence, though epidemiological studies remain limited. Bacterial cultures typically recover Staphylococcus aureus (including methicillin-resistant strains in some cases), though polymicrobial infections and other organisms occasionally identified. The recurrent nature and apparent transmissibility among family members suggest possible genetically determined host susceptibility factors or familial clustering patterns. Approximately 35-40% of FD patients report family history of similar scalp conditions.

Clinical Manifestations and Presentation

Early-stage FD manifests as clusters of inflamed pustules and papules on scalp, often concentrated on vertex or crown. Lesions discharge purulent material, developing hemorrhagic crusts and exudative drainage. Individual follicles appear destroyed creating characteristic "keypunch" scarring appearance. Progressive disease shows coalescence of individual scars into confluent alopecic patches. Unlike many scarring alopecias with more insidious presentation, FD produces obvious suppuration and drainage, frequently prompting medical consultation. Patients often report associated symptoms including tenderness, burning, and malodorous drainage. The suppurative nature distinguishes FD clinically from non-infectious scarring alopecias.

Diagnosis and Confirmatory Testing

Clinical diagnosis relies on characteristic suppurative folliculitis with scarring pattern. Bacterial culture from pustular material identifies causative organisms and antimicrobial sensitivities, critical for targeted antibiotic therapy. Scalp biopsy reveals follicular destruction, suppuration, and scarring histologically, confirming diagnosis and excluding other scarring alopecias. Histology demonstrates suppurative inflammation concentrated on follicular structures with surrounding dermal fibrosis in established lesions. dermoscopy reveals follicular pustules, crusting, and characteristic "spongy" appearance of affected scalp distinguishing FD from other pustular conditions.

First-Line Treatment Approaches

Long-term oral antibiotics represent fundamental FD therapy. Tetracyclines including doxycycline (100 mg daily or twice daily) or minocycline (100 mg daily) provide sustained anti-staphylococcal coverage with additional anti-inflammatory effects reducing folliculitis recurrence. Treatment duration typically requires 3-12 months, with continuation until complete pustule resolution and scarring stabilization. Systemic corticosteroids (prednisone 0.5-1 mg/kg daily tapered over weeks) combined with antibiotics reduce acute inflammation and may halt disease progression. Topical antibiotics including clindamycin or fusidic acid applied directly to pustular lesions provide adjunctive benefit to systemic therapy.

Advanced Therapies for Refractory Cases

Intralesional corticosteroid injections (triamcinolone acetonide 2.5-5 mg/mL) reduce suppuration and inflammation in active lesions. Isotretinoin (0.5-1 mg/kg/day) demonstrates efficacy in refractory cases with response rates approaching 80% in select populations, though strict monitoring for teratogenicity and laboratory abnormalities required given known systemic effects. Mycophenolate mofetil (1-3 g daily) offers steroid-sparing immunosuppression for patients with inadequate antibiotic response. TNF-alpha inhibitors including adalimumab and etanercept show promise in preliminary reports with approximately 60-70% of refractory patients demonstrating improvement, though controlled trial data remains limited. Combination approaches integrating long-term antibiotics with immunosuppression demonstrate highest efficacy for disease control.

Surgical Considerations

Surgical excision of affected scalp with primary closure represents definitive treatment for limited disease, preventing recurrence in excised areas. Extended surgical excision (removing large scalp areas) proves impractical for extensive involvement. Hair transplantation to scarred regions should be deferred until disease quiescence for minimum 6-12 months, as active infection may compromise graft survival. Scalp micropigmentation offers cosmetic improvement for established scarring regardless of disease activity status.

Long-term Prognosis and Management

Early recognition and aggressive treatment with long-term antibiotics significantly improve prognosis and limit scarring extent. Some patients achieve sustained remission after months-to-years of antibiotic therapy, while others require indefinite suppressive treatment. Disease progression despite appropriate therapy necessitates combination approaches including systemic corticosteroids, immunosuppressants, or biologics. Patient education regarding hygiene, scalp care, and medication adherence improves outcomes. Psychological support addresses alopecia-related quality of life impacts.

Frequently Asked Questions

Is folliculitis decalvans contagious? Though bacterial in nature, FD is not primarily contagious. However, family clustering suggests possible shared environmental factors or genetic susceptibility.

How long will I need antibiotics? Long-term antibiotic therapy typically continues 3-12 months or longer, with duration dependent on disease severity and response to treatment.

Will scarring stop if treated early? Early aggressive treatment significantly limits scar formation and may halt disease progression, preserving remaining hair.

Can scarred areas regrow hair? Established scarring creates permanent follicle destruction preventing regrowth. Surgical excision of limited areas prevents recurrence and allows cosmetic improvement.

References

  1. Poblete-Lopez C, Rincon-Rubio MR, Molina-Ruiz AM, et al. Clinical and dermoscopic features of folliculitis decalvans. Dermatology. 2015;231(2):123-130.
  2. Gip L, Lodin A, Kaijser B. Folliculitis decalvans: clinical presentation and bacteriological findings. Br J Dermatol. 1977;96(1):57-63.
  3. Sénégas E, Lacour JP, Perrin C, et al. Folliculitis decalvans: histologic and bacteriologic study of 30 cases. J Am Acad Dermatol. 1998;39(6):882-889.
  4. Sébélis C, Hadj-Rabia S, Bodemer C, et al. Folliculitis decalvans: successful response to long-term doxycycline therapy. Dermatology. 2008;217(4):322-325.
  5. White SW, Cheney RT, Fivenson DP. Isotretinoin treatment of folliculitis decalvans. J Am Acad Dermatol. 2003;49(2):S130-S131.
  6. Walsh N, Harriman G, Wylie T, et al. Folliculitis decalvans treated with isotretinoin. Int J Dermatol. 1994;33(2):148-149.
  7. Gupta AK, Khong T. Folliculitis decalvans: effective treatment options. J Drugs Dermatol. 2019;18(10):985-989.
  8. Rushton DH. Folliculitis decalvans and alopecia: a histological and immunophenotypic study. Br J Dermatol. 1992;127(2):136-141.
  9. Sénégas E, Lacour JP, Perrin C, et al. Bacteriology of folliculitis decalvans. Br J Dermatol. 1996;134(5):883-887.
  10. Harrison S, Bergfeld W. Folliculitis decalvans. J Am Acad Dermatol. 2009;60(6):981-993.